Bone metastasis is an advanced stage of malignant tumor disease progression, especially common in breast cancer, prostate cancer, lung cancer, colorectal cancer and other tumors. The pain associated with bone metastases often seriously interferes with patients’ ability to live and affects their quality of life. A comprehensive treatment strategy should be adopted for bone metastases from malignant tumors, including systemic antitumor therapy, pharmacological analgesic therapy to relieve painful symptoms, bisphosphonate therapy to prevent and reduce bone-related events, radiation therapy to relieve compressive neuralgia or reduce the risk of weight-bearing bone fracture, and surgical treatment. I. Anti-tumor therapy Bone metastases are mostly local manifestations of systemic tumor metastases, and systemic therapy against the tumor should be the main choice for treatment and control of the tumor. Clinicians and patients must realize that the pain of bone metastasis is produced by the progress of malignant tumor, and only when the systemic antitumor treatment is effective, the pain can be fundamentally controlled. Therefore, antitumor treatment must be regarded as the most important basic treatment of analgesic treatment, and only analgesic treatment based on this foundation can bring long-term pain control to patients. B. Standardized treatment of analgesic drugs Bone metastasis pain, as a special type of pain, should also follow the principles of standardized treatment of pain. 1. Cancer pain assessment. It mainly includes the nature and degree of cancer pain. At present, cancer pain is mostly divided into three categories: somatic pain, visceral pain and neuralgia. The pain of cancer patients is mostly mixed. The assessment of the degree of cancer pain is relatively simple, but attention should be paid to the assessment of elderly patients, patients with language or cognitive dysfunction. Bone metastasis pain often includes dull pain due to local injury of bone metastasis, nerve compression pain due to structural changes at the site of bone metastasis, and pain due to pathological fracture. Since these types of pain are handled differently, it is especially important to conduct detailed pain assessment. 2. Opioid therapy. For patients using opioids for the first time, especially strong opioids, the pain relief process should include a short-acting opioid titration phase and a controlled-release opioid maintenance treatment phase. The purpose of short-acting opioid titration is to find an effective pain-relieving dose suitable for the patient in a short period of time, and then convert to controlled and sustained-release dosage after the pain is satisfactorily controlled for easy administration. 3.Refractory cancer pain treatment. Most cancer pains can be satisfactorily controlled by drug therapy, while refractory pains are those that cannot be satisfactorily controlled by pain relief drug therapy or have intolerable side effects. The etiology of cancer refractory pain is complex, and neuropathic pain is a common etiology, and its formation mechanism is complicated, which requires combined drugs for pain relief. Part of the bone metastasis pain is neuropathic pain, and the combined application of glucocorticoids and anticonvulsants should generally be an important choice in the comprehensive treatment. Third, other treatment Bisphosphonate therapy. Hypercalcemia, bone pain and bone-related events are common complications in patients with bone metastases, which will seriously affect patients’ quality of life, aggravate their psychological stress and shorten their survival time. Bisphosphonates are an important drug of choice for patients with bone metastases and have significant efficacy in reducing the incidence of bone-related events in patients with bone metastases. The third-generation bisphosphonate zoledronic phosphate is superior to the second-generation drug pamiphosphate disodium in controlling bone metastasis pain. However, during the application of bisphosphonates, care should be taken to prevent their toxic side effects, especially osteomyelitis of the maxillofacial mandible.